ARPA-H Funding And US Provider Deal Will Expand Imaging Access

Key Takeaways

• Expanded partnerships and government-backed projects diversify revenue streams, reduce financial risk, and position Micro-X for long-term, sustainable growth.
  
• Progress in portable and full-body CT technologies, supported by strong funding, enhances access to growing healthcare markets and supports margin improvement.
  
• Persistent cash outflows, dependence on milestone funding, and concentrated product risk expose Micro-X to financial instability, unpredictable revenue, and intensified competition impacting growth and profitability.

Catalysts

Designs, develops, manufactures, and commercializes healthcare and security markets products using micro-X proprietary cold cathode X-ray technology in Australia, the United States, Asia-Pacific, Europe, the Middle East, and Africa.

• Recent supply agreement with a major U.S. healthcare provider gives Micro-X frictionless access to a vast network of 700 healthcare facilities, positioning the company to capture growing demand for portable diagnostic imaging driven by the aging global population and increased healthcare spending-potentially driving substantial revenue uplift and improved sales momentum.
  
• Ongoing progress and near-term expected hospital trials for Micro-X's head CT scanner, supported by government (MRFF) funding, creates strong optionality for entry into the growing market for point-of-care stroke diagnosis, which could significantly expand addressable market and drive future revenue growth pending successful trials and regulatory approval.
  
• Advancement of full-body portable CT scanner supported by milestone-based ARPA-H funding validates Micro-X's technology and provides non-dilutive capital; as this product progresses, it leverages trends in digitization and miniaturization in healthcare, enhancing the company's future revenue diversity and supporting higher gross margins.
  
• Strategic partnerships in the security imaging segment (DHS, Billion Prima) introduce recurring annuity-like revenue streams as partner companies commercialize their products embedding Micro-X's core technology, reducing dependence on single product lines and increasing operating leverage, supporting long-term earnings growth.
  
• Execution on multiple government-funded and partnered projects reduces capital expenditure burden and improves cash flow outlook, enabling sustained R&D and scaling without immediate reliance on dilutive equity raises; this improves the potential for margin expansion and long-term sustainable earnings growth.

Micro-X Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Micro-X's revenue will grow by 42.6% annually over the next 3 years.
• Analysts are not forecasting that Micro-X will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Micro-X's profit margin will increase from -76.3% to the average AU Medical Equipment industry of 9.6% in 3 years.
• If Micro-X's profit margin were to converge on the industry average, you could expect earnings to reach A$3.9 million (and earnings per share of A$0.01) by about August 2028, up from A$-10.8 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 35.8x on those 2028 earnings, up from -4.8x today. This future PE is lower than the current PE for the AU Medical Equipment industry at 40.6x.
• Analysts expect the number of shares outstanding to grow by 0.27% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Micro-X Future Earnings Per Share Growth

Risks

• Ongoing negative operating cash flow and a reported net outflow of $3.5 million for the quarter-despite milestone payments and overdue receivables-raise concerns about Micro-X's ability to achieve sustainable profitability and could drive future shareholder dilution through additional capital raisings, impacting earnings per share and net margins.
  
• Reliance on milestone
• and project-based funding from partners such as DHS, ARPA-H, and Billion Prima introduces significant revenue timing uncertainty; delays in achieving technical milestones, regulatory approvals, or partner commercialization could result in unpredictable or postponed cash inflows, placing strain on working capital and revenue reliability.
  
• The bulk of medical imaging revenue growth is tied to breakthrough agreements (e.g., the major U.S. healthcare supply deal) that feature no minimum orders and whose sales conversion is highly dependent on successful internal marketing and adoption, exposing Micro-X to the risk of slow revenue ramp and lower-than-anticipated sales, impacting top-line growth and operating leverage.
  
• Heavy dependence on a single technology platform (cold cathode/carbon nanotube X-ray) and a concentrated product pipeline (notably the Rover Plus and head CT) leaves the company vulnerable to technology risk and potential obsolescence if a superior imaging modality emerges, threatening long-term revenue stability and market share.
  
• The medtech imaging industry is highly competitive, with major multinationals better positioned to absorb R&D costs, navigate regulatory complexity, and exert pricing pressure-any lag in Micro-X's innovation pace, manufacturing scale-up, or regulatory approvals could compress gross margins, necessitate higher investment, and erode profitability.

Valuation

• The analysts have a consensus price target of A$0.17 for Micro-X based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be A$41.0 million, earnings will come to A$3.9 million, and it would be trading on a PE ratio of 35.8x, assuming you use a discount rate of 7.3%.
  
• Given the current share price of A$0.08, the analyst price target of A$0.17 is 54.7% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.